1018.0000 3.80 (0.37%)
NSE Jun 16, 2025 15:31 PM
Volume: 99,404
 

1018.00
0.37%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Number of FII/FPI investors increased from 92 to 105 in Mar 2025 qtr.
More from Alivus Life Sciences Ltd.
Recommended